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ABSTRACT
Objectives To evaluate the cardiovascular outcomes and
other outcomes associated with angiotensin receptor
blockers.
Design Systematic review of randomised controlled trials
with meta-analysis and trial sequential analysis (TSA).
Data sources and study selection Pubmed, Embase, and
CENTRAL searches for randomised clinical trials, until
August 2010, of angiotensin receptor blockers compared
with controls (placebo/active treatment) that enrolled at
least 100 participants and had a follow-up of at least one
year.
Data extraction Myocardial infarction, death,
cardiovascular death, angina pectoris, stroke, heart
failure, and new onset diabetes.
Results 37 randomised clinical trials included 147020
participants and had a total follow-up of 485166 patient
years. When compared with controls (placebo/active
treatment), placebo, or active treatment, angiotensin
receptor blockers were not associatedwith an increasein
the risk of myocardial infarction (relative risk 0.99, 95%
confidence interval 0.92 to 1.07), death, cardiovascular
death, or angina pectoris. Compared with controls,
angiotensin receptor blockers were associated with a
reduction in the risk of stroke (0.90, 0.84 to 0.98), heart
failure(0.87,0.81to0.93),andnewonsetdiabetes(0.85,
0.78 to 0.93), with similar results when compared with
placebo or with active treatment. Based on trial
sequential analysis, there is no evidence even for an
average 5.0-7.5% (upper confidence interval 5-11%)
relative increase in myocardial infarction (absolute
increase of 0.3%), death, or cardiovascular death with
firm evidence for relative risk reduction of stroke (at least
1%, average 10%) (compared with placebo only), heart
failure (at least 5%, average 10%), and new onset
diabetes (at least 4%, average 10%) with angiotensin
receptor blockers compared with controls.
Conclusions This large and comprehensive analysis
produced firm evidence to refute the hypothesis that
angiotensin receptor blockers increase the risk of
myocardial infarction (ruling out even a 0.3% absolute
increase). Compared with controls, angiotensin receptor
blockers reduce the risk of stroke, heart failure, and new
onset diabetes.
INTRODUCTION
Theprovocative editorialby Verma and Straussin the
BMJin2004
1statingthatangiotensinreceptorblockers
“may increase myocardial infarction—and patients
may need to be told” led to extensive scrutiny of out-
come data with these drugs. This controversy was a
directfalloutfromthepublicationofthevalsartananti-
hypertensivelongtermuseevaluation(VALUE)trial,
2
in which the primary hypothesis stated that “in hyper-
tensive patients at high cardiovascular risk, for the
same level of blood pressure control, valsartan will be
more effective than amlodipine in reducing cardiac
morbidity and mortality.” Unexpectedly, there was a
significant 19% relative increase in the prespecified
secondary outcome measure of myocardial infarction
in the valsartan arm compared with the amlodipine
arm.
In 2008 a Cochrane Collaboration review found
angiotensin receptor blockers to be as effective as
angiotensin converting enzyme inhibitors at reducing
blood pressure, though the effect was modest.
34 The
blood pressure lowering treatment trialists’ collabora-
tion has shown similar blood pressure dependent
effects of angiotensin converting enzyme inhibitors
andangiotensinreceptorblockersfortheriskofstroke,
coronary heart disease, and heart failure.
5 The authors
cautioned,however,thattherewasevidenceofablood
pressureindependenteffectontheriskofmajorcoron-
ary disease events only for angiotensin converting
enzyme inhibitors, not for angiotensin receptor block-
ers. In addition, more recent trials like the Ongoing
Telmisartan Alone and in Combination with Ramipril
Global Endpoint Trial (ONTARGET),
6 a thorough,
double blind prospective randomised trial, documen-
ted equal outcome efficacy of an angiotensin receptor
blocker (telmisartan) and an angiotensin converting
enzyme inhibitor in a high risk population, though
there was a trend towards better prevention of stroke
in the angiotensin receptor blocker arm and towards
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angiotensin converting enzyme inhibitor (ramipril)
arm.
We evaluated the risk of cardiovascular and other
outcomes with angiotensin receptor blockers in gen-
eralandtestedthehypothesisofincreasedriskofmyo-
cardial infarction with angiotensin receptor blockers
found in previous studies and analyses.
METHODS
Eligibility criteria
WesearchedPubmed,Embase,andCENTRALusing
the terms: ‘angiotensin receptor blockers’, ‘angioten-
sin receptor antagonists’, ‘ARBs’, and the names of
individual angiotensin receptor blockers in humans
until August 2010. Appendix 1 on bmj.com gives
details of the search and the MeSH terminologies
used. We checked the reference lists of review articles,
meta-analyses, and original studies identified by the
electronic searches to find other eligible trials. There
was no language restriction for the search. Authors of
trials were contacted when results were unclear or
when relevant data were not reported. In addition,
we searched Food and Drug Administration (FDA)
dockets by hand searching all documents submitted
for drug approval/labelling change as well as the min-
utesfromFDAmeetingsavailableontheFDAwebsite.
There was no formal protocol for this systematic
review.
To be included in this analysis, eligible trials had to
fulfilthefollowingcriteria:randomisedclinicaltrialsof
participants comparing angiotensin receptor blockers
with controls (placebo or active treatment); follow-up
of at least one year; at least 100 participants enrolled;
and reporting any of myocardial infarction, death,
cardiovasculardeath,anginapectoris,stroke,heartfail-
ure, andnewonsetdiabetes mellitus. Weexcludedstu-
dies in which angiotensin receptor blockers were not
first line agents or studies/treatment arms in which
angiotensin receptor blockers were used in combina-
tion with an angiotensin converting enzyme inhibitor.
Selection and quality assessment
Two authors (SB and SK) independently assessed trial
eligibility and risk of trial bias and extracted data
(κ=0.96). Disagreements were resolved by consensus.
The risk of bias was assessed by using the components
recommended by the Cochrane Collaboration
7:
sequence generation of allocation; allocation conceal-
ment; blinding of participants, staff, and outcome
assessors;incompleteoutcomedata;selectiveoutcome
reporting; and other sources of bias. The trials did not
differforthelastthreecomponents.Trialswithhighor
unclear risk for bias for any one of the first three com-
ponents were considered as at high risk of bias. Other-
wise, they were considered as low risk of bias.
Data extraction and synthesis
We evaluated myocardial infarction, death, cardio-
vascular death, angina pectoris, stroke, heart failure,
and new onset diabetes mellitus. In all of the analyses
reported, “control” refers to either placebo or active
treatment comparator.
Statistical analysis
We carried out an intention to treat meta-analysis in
line with recommendations from the Cochrane Colla-
boration and the PRISMA statement
78using standard
software (Stata 9.0, StataCorp, TX).
9 Heterogeneity
was assessed with the I
2 statistic.
10 I
2 is the proportion
of total variation observed between the trials attributa-
ble to differences between trials rather than sampling
error (chance) with I
2 <25% considered as low and I
2
>75% as high. The pooled effect for each grouping of
trials was derived from the point estimate for each
separate trial weighted by the inverse of the variance
(1/SE²). The risk ratio was calculated with the random
effectsmodelofDerSimonianandLaird.
11Publication
bias was estimated visually with funnel plots and with
Begg’stestand the weighted regressiontestof Egger.
12
Given that the results might be different based on the
comparisongroup(placebovactivetreatment),weper-
formed the primary analyses after stratifying the stu-
dies based on the comparator (placebo v active
treatment).
Subgroup analyses
Weperformedsubgroupanalysesoftrialswithlowrisk
of bias compared with trials with high risk of bias and
cohort enrolled (hypertension v non-hypertension)
trials. We estimated the difference between the esti-
mates of the subgroups according to tests for inter
action.
13 P<0.05 indicates that the effects of treatment
differ between the tested subgroups.
Trial sequential analysis
In a single trial, interim analyses increase the risk of
type I error. To avoid an increase of overall type I
error, monitoring boundaries can be applied to decide
Records identified through databases search (n=1470)
Articles retrieved for detailed evaluation (n=213)
Articles retrieved for further evaluation (n=58)
Chosen for final analyses (n=37)
Excluded (after reading title/abstract) as
did not satisfy inclusion criteria (n=1257)
Excluded (n=155):
  Sample size <100 (n=88)
  Follow-up <1 year (n=45)
  Duplicate publications (n=22)
Excluded (n=21):
  ARBs not first line treatment (n=4)
  Post hoc analysis of randomised controlled trials (n=6)
  Not evaluating outcomes of interest (n=6)
  Meta-analysis (n=5)
Fig 1 | Study identification, selection, and exclusions
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early because of the P value being sufficiently small.
Because no reason exists why the standards for a
meta-analysis should be less rigorous than those for a
single trial, analogous trial sequential monitoring
boundaries can be applied to meta-analysis as trial
sequential analysis.
1415 Cumulative meta-analyses of
trials are at risk of producing random errors because
of fewdata and repetitivetesting of accumulatingdata,
and the requirement for the amount of information
analogoustothesamplesizeofasingleoptimallypow-
ered clinical trial might not be met.
1415
The underlying assumption for trial sequential ana-
lysis is that significance testing and calculation of the
confidence intervals are performed each time a new
trial is published. Trial sequential analysis depends
on the quantification of the required amount of infor-
mation. In this context, the smaller the required
amount, the more lenient the trial sequential analysis,
thusthemorelenientthecriteriaforsignificance.
1415A
required diversity (D
2) adjusted information size was
calculated, D
2 being the relative variance reduction
when the meta-analysis model is changed from a ran-
domeffectsintoafixedeffectmodel.
16D
2isthepercen-
tageofthevariabilitybetweentrialsandconstitutesthe
sumofthevariabilitybetweentrials.Itisanestimateof
sampling error after consideration of the required
information size. D
2 is different from the intuitively
Table 1 |Baseline characteristics of trials included in systematic review of angiotensin receptor blockers and risk of myocardial infarction
Trial
No of
people Comparison Cohort
Follow-up
(years) Age(years)
Diabetes
(%)
Hyperten-
sion (%)
ALPINE, 2003
19 393 Candesartan v HCTZ Hypertension 1 55 48 100
CASE-J, 2008
20 4703 Candesartan v amlodipine Hypertension 3.2 64 55 100
CHARM-added, 2003
21 2548 Candesartan v placebo Heart failure 3.4 64 79 48.2
CHARM-alternative, 2003
22 2028 Candesartan v placebo Heart failure 2.8 66 68 50
CHARM-preserved, 2003
23 3023 Candesartan v placebo Heart failure 3 67 60 64.3
DETAIL, 2004
24 250 Telmisartan v enalapril Hypertension, diabetes with nephropathy 5 61 73 100
DIRECT-Prevent 1, 2008
25-26 1421 Candesartan v placebo Normotensive, DM type 1 without retinopathy 4.7 30 57 0
DIRECT-Protect 1, 2008
25-26 1905 Candesartan v placebo Normotensive, DM type 1 with retinopathy 4.8 32 58 0
DIRECT-Protect 2, 2008
25 27 1905 Candesartan v placebo Normotensive, DM type 2 with retinopathy 4.7 57 50 62
E-COST, 2005
28 2048 Candesartan v conventional Hypertension 3.1 66.9 48 100
E-COST-R, 2005
29 141 Candesartan v conventional Hypertension with CRI 3.1 67 59 100
ELITE, 1997
30 722 Losartan v captopril Heart failure 1 74 67 57
ELITE II, 2000
31 3152 Losartan v captopril Heart failure 1.5 71 30 49
GISSI-AF, 2009
32 1442 Valsartan v placebo Atrial fibrillation 1 68 62 85.3
HIJ-CREATE, 2009
33 2049 Candesartan v conventional Hypertension and CAD 4.2 65 20 100
IDNT (CCB), 2003
34 1146 Irbesartan v amlodipine DM 2 and nephropathy 2.6 59 64 100
IDNT (placebo), 2003
34 1148 Irbesartan v placebo DM 2 and nephropathy 2.6 59 68 100
I-Preserve, 2008
35-36 4128 Irbesartan v placebo Heart failure 4.1 72 40 88.5
IRMA 2, 2001
37 611 Irbesartan v placebo Hypertensive, diabetes with microalbuminuria 2 58 68 100
JIKEI, 2007
38 3081 Valsartan v conventional Hypertension 3.1 65 66 87.5
Kondo et al, 2003
39 406 Candesartan v control CAD 2 65 76 43.5
KYOTO, 2009
40 3031 Valsartan v conventional Hypertension 3.3 66 57 100
LIFE, 2002
41 9193 Losartan v atenolol Hypertension 4.8 67 46 100
MOSES, 2005
42 1352 Eprosartan v nitrendipine Hypertensive with stroke 2.5 68 54 100
NAVIGATOR, 2010
43 9306 Valsartan v placebo Impaired glucose tolerance 6.5 64 49 77.5
ONTARGET, 2008
6 17 118 Telmisartan v ramipril Vascular disease 4.7 66 73 69
OPTIMAAL, 2002
44 5477 Losartan v captopril AMI 2.7 67 71 36
PRoFESS, 2008
45 20 332 Telmisartan v placebo Stroke 2.5 66 64 74
RASS (ACEi), 2009
46 190 Losartan v enalapril DM 1, normotensive 5 30 47 0
RASS (placebo), 2009
46 191 Losartan v placebo DM 1, normotensive 5 29 46 0
RENAAL, 2001
47 1513 Losartan v placebo DM 2 and nephropathy 3.4 60 63 93.5
ROAD, 2007
48 360 Losartan v benazepril CRI without DM 3.7 50 NR 63
SCOPE, 2003
49 4937 Candesartan v placebo Hypertension 3.7 76 36 100
Suzuki, 2008
50 366 ARB v control Hypertension and haemodialysis 3 60 59 93
Takahashi et al, 2006
51 80 Candesartan v control Hypertensive and haemodialysis 1.6 61 59 81
TRANSCEND, 2008
52 5926 Candesartan v placebo Vascular disease 4.7 67 57 76.5
VAL-Heft, 2001
53 5010 Valsartan v placebo Heart failure 1.9 63 80 NR
VALIANT, 2003
54 9818 Valsartan v captopril Heart failure 2 65 69 55.5
VALUE, 2004
2 15 245 Valsartan v amlodipine Hypertension 4.2 67 58 100
AMI=acute myocardial infarction; ARB=angiotensin receptor blockers; CAD=coronary artery disease; CRI=Chronic renal insufficiency; CCB= calcium channel blockers; DM=diabetes mellitus.
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fication of heterogeneity, the inconsistency (I
2), which
might underestimate the required information size.
16
The trial sequential analysis was performed with a
desire to maintain an overall 5% risk of type I error,
beingthestandardinmostmeta-analysesandsystema-
ticreviews,andwecalculatedtherequiredinformation
size (that is, the meta-analysis information size needed
to detect or reject an intervention effect of a 20% rela-
tive risk reduction for benefit but a stricter more rigor-
ous sequential testing of a 10% and then a 2.5-7.5%
relative risk increase for harms, with a risk of type II
error of 10-20%, at a power of 80-90%).
1415
RESULTS
Study selection
We identified 37 trials (39 comparator arms) that satis-
fied our inclusion criteria (fig 1). The 39 comparator
arms included 17 arms that compared angiotensin
receptor blockers with placebo and 22 arms that com-
pared angiotensin receptor blockers with active treat-
ment (table 1). We excluded the combination arms
Table 2 |Blood pressure, dose of drugs used, and quality of included trials in systematic review of angiotensin receptor
blockers and risk of myocardial infarction
Trial
Baseline blood
pressure*
Final blood
pressure* Quality of
study†
Mean dose
(mg) Source of data ARB Control ARB Control
ALPINE
19 155/97 155/97 134/83 132/84 +++ NR Published
CASE-J
20 163/92 163/92 136/77 134/77 +++ NR Published
CHARM-added
21 125/75 126/75 NR NR +++ 24 Published and FDA dockets
CHARM-alternative
22 130/77 130/77 NR NR +++ 23 Published and FDA dockets
CHARM-preserved
23 136/78 136/78 NR NR +++ 25 Published and FDA dockets
DETAIL
24 153/85 152/86 146/79 149/82 +++ NR Published
DIRECT-Prevent 1
25-26 116/72 116/72 NR NR +++ NR Published
DIRECT- Protect 1
25-26 117/74 117/73 NR NR +++ NR Published
DIRECT- Protect 2
25 27 131/77 131/78 NR NR +++ NR Published
E-COST
28 162/91 166/96 140/79 138/81 ++− 7 Published
E-COST-R
29 145/79 145/79 134/73 133/74 ++− 7 Published
ELITE
30 137/79 137/79 NR NR +++ 42.6 Published
ELITE II
31 134/78 134/78 NR NR +++ NR Published
GISSI-AF
32 138/82 139/82 134/NR 137/NR +++ NR Published
HIJ-CREATE
33 135/76 136/76 132/73 128/72 ++− NR Published
IDNT (CCB)
34 160/87 159/87 140/77 141/77 +++ NR Published and FDA dockets
IDNT (Placebo)
34 160/87 158/87 140/77 144/80 +++ NR Published and FDA dockets
I-Preserve
35 36 137/79 136/79 133/78 134/78 ++− 275 Published
IRMA 2
37 153/90 153/90 142/83 144/83 +++ NR Published and FDA dockets
JIKEI
38 139/81 139/81 131/77 132/78 ++− NR Published
Kondo et al
39 129/76 128/76 127/75 126/76 ±±± NR Published
KYOTO
40 157/88 157/88 133/76 133/76 ++− NR Published
LIFE
41 174/98 175/98 144/81 145/81 +++ 82 Published
MOSES
42 151/84 152/87 138/81 136/80 ++− 623 Published
NAVIGATOR
43 139/83 140/83 133/78 136/80 +++ NR Published
ONTARGET
6 142/82 142/82 NR NR +++ NR Published
OPTIMAAL
44 123/72 123/71 NR NR +++ 45 Published
PRoFESS
45 144/84 144/84 NR NR +++ NR Published
RASS (ACEi)
46 120/70 120/71 115/66 113/66 ++± NR Published
RASS (Placebo)
46 120/70 119/70 115/66 117/68 ++± NR Published
RENAAL
47 152/82 153/82 140/74 142/74 +++ NR Published and FDA dockets
ROAD
48 151/86 150/86 NR NR ++− NR Published
SCOPE
49 166/90 167/90 145/80 149/82 +++ 11.6 Published
Suzuki
50 154/81 156/82 140/80 140/78 ±±− NR Published
Takahashi et al
51 153/82 152/85 153/83 149/80 ++− NR Published
TRANSCEND
52 141/82 141/82 NR NR +++ NR Published
VAL-Heft
53 123/76 124/76 118/NR 123/NR +++ 254 Published and FDA dockets
VALIANT
54 123/72 123/72 127/75 127/76 +++ 247 Published and FDA dockets
VALUE
2 155/87 155/88 139/79 138/78 +++ 151.7 Published
NR=not reported; FDA=Food and Drug Administration.
*Diastolic/systolic mm Hg.
†Risk of bias according to sequence generation of allocation, allocation concealment, and blinding; + represents low bias risk, − high bias risk, and ±
unclear. bias risk.
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tensin receptor blocker) of the ONTARGET
6 and the
VALIANT
54 trials.
Baseline characteristics
Tables 1 and 2 summarise the baseline characteristics
oftheincludedtrials.The37trialsrandomised147020
participants, 73298 (49.8%) to angiotensin receptor
blockers and 73722 (50.2%) to controls. The average
follow-upwas3.3years(range1-6.5years),withatotal
follow-up across all trials of 485166 patient years.
Among the 37 randomised controlled trials, 12 were
considered at high risk of bias (table 2) and the rest as
low risk. Data on outcomes were abstracted both from
the original publication and the Food and Drug
Administration dockets (when available) (table 2).
Placebo
  CHARM-alternative22
  CHARM-preserved
23
  CHARM-added21
  I-Preserve35-36
  IDNT (placebo)
34
  IRMA 2
37
  NAVIGATOR43
  PRoFESS45
  RENAAL
47
  SCOPE
49
  TRANSCEND52
Random effects subtotal:
  I2=50.7%, P=0.027
Fixed effects subtotal 
Active
  ALPINE19
  CASE-J20
  DETAIL24 
  E-COST28 
  E-COST-R29 
  ELITE30
  ELLITE II31 
  HIJ-CREATE33 
  IDNT (CCB)34
  JIKEI
38
  KYOTO
40 
  Kondo et al39 
  LIFE41
  MOSES
42 
  ONTARGET6 
  OPTIMAAL44
  ROAD48
  Suzuki
50
  VALIANT
54 
  VALUE2
Random effects subtotal:
  I2=1.2%, P=0.442
Fixed effects subtotal 
Random effects overall:
  I
2=30.7%, P=0.055
Fixed effects overall 
P=0.15 for interaction
1.57 (1.10 to 2.23)
0.78 (0.55 to 1.09)
0.64 (0.44 to 0.92)
1.11 (0.77 to 1.59)
0.94 (0.63 to 1.40)
0.51 (0.15 to 1.75)
1.00 (0.79 to 1.25)
1.00 (0.81 to 1.23)
0.75 (0.53 to 1.06)
1.10 (0.79 to 1.54)
0.79 (0.63 to 1.01)
0.93 (0.81 to 1.07)
0.94 (0.85 to 1.03)
1.00 (0.06 to 15.79)
0.94 (0.49 to 1.82)
1.63 (0.60 to 4.43)
0.41 (0.20 to 0.86)
2.09 (0.40 to 11.03)
0.26 (0.03 to 2.34)
1.10 (0.67 to 1.83)
1.12 (0.66 to 1.88)
1.60 (1.00 to 2.54)
0.89 (0.47 to 1.71)
0.64 (0.25 to 1.63)
2.00 (0.18 to 21.88)
1.05 (0.86 to 1.28)
0.80 (0.53 to 1.21)
1.07 (0.94 to 1.22)
1.01 (0.89 to 1.15)
1.00 (0.25 to 3.94)
0.80 (0.22 to 2.93)
0.99 (0.87 to 1.13)
1.17 (1.01 to 1.36)
1.04 (0.98 to 1.11)
1.04 (0.98 to 1.11)
0.99 (0.92 to 1.07)
1.01 (0.96 to 1.06)
3
4
3
3
3
<1
6
6
3
4
6
41
<1
1
1
1
<1
<1
2
2
2
1
1
<1
7
3
10
10
<1
<1
10
9
59
100
0.1 1 10
Trial
ARBs better Control better
Relative risk
(95% CI)
Relative risk
(95% CI)
Weight
(%)
75/1013
57/1514
44/1276
60/2067
44/579
5/404
138/4631
168/10 146
50/751
70/2477
116/2954
827/27 812
1/197
17/2354
9/120
10/1053
4/69
1/352
31/1578
29/1024
44/579
17/1541
7/1517
2/203
198/4605
39/681
440/8542
384/2744
4/180
4/183
397/4909
369/7649
2007/40 080
2834/67 892
ARBs
48/1015
73/1509
69/1272
54/2061
46/569
5/207
140/4675
169/10 186
68/762
63/2460
147/2972
882/27 688
1/196
18/2349
6/130
23/995
2/72
4/370
28/1574
26/1025
27/567
19/1540
11/1514
1/203
188/4588
48/671
413/8576
379/2733
4/180
5/183
402/4909
313/7596
1918/39 971
2088/67 659
Control
Events
Fig 2 |Angiotensin receptor blockers (ARBs) and myocardial infarction, stratified by comparison group (placebo v active
treatment)
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Angiotensin receptor blockers were not associated
with any increase in the risk of myocardial infarction
when compared with controls (relative risk 0.99, 95%
confidence interval 0.92 to 1.07; P=0.85) (fig 2). The
results were similar when angiotensin receptor
blockers were compared with either placebo or with
active treatment (P=0.15 for interaction) (fig 2). There
was low to moderate heterogeneity and no evidence
for publication bias (see fig A1 in appendix 2 on
bmj.com). Similarly, angiotensin receptor blockers
were not associated with any increase in the risk of
Placebo
  CHARM-alternative
22
  CHARM-preserved
23
  CHARM-added21
  DIRECT- Prevent 1
25 26
  DIRECT- Protect 1
25 26
  DIRECT- Protect 225 27
  GISSI-AF32
  I-Preserve
35-36
  IDNT (placebo)
34
  IRMA 237
  NAVIGATOR
43
  PRoFESS45
  RASS (placebo)46
  RENAAL47
  SCOPE49
  TRANSCEND52
  VAL-Heft53
Random effects subtotal:
  I
2=0.0%, P=0.952
Fixed effects subtotal 
Active
  CASE-J
20
  DETAIL
24 
  E-COST
28 
  E-COST-R
29 
  ELITE
30
  ELLITE II
31 
  HIJ-CREATE
33 
  IDNT (CCB)
34
  JIKEI
38
  KYOTO
40 
  Kondo et al
39 
  LIFE
41
  MOSES
42 
  ONTARGET
6 
  OPTIMAAL
44
  RASS (ACEi)
46
  Suzuki
50
  Takahashi et al
51
  VALIANT54 
  VALUE
2
  ALPINE
19
  ROAD
48
Random effects subtotal:
  I
2=30.8%, P=0.094
Fixed effects subtotal 
Random effects overall:
  I
2=0%, P=0.482
Fixed effects overall 
P=0.99 for interaction
0.90 (0.78 to 1.03)
1.03 (0.87 to 1.21)
0.91 (0.81 to 1.02)
1.40 (0.45 to 4.38)
0.88 (0.32 to 2.41)
1.06 (0.67 to 1.67)
1.14 (0.42 to 3.13)
1.02 (0.91 to 1.14
0.92 (0.70 to 1.20)
1.13 (0.40 to 3.20)
0.91 (0.78 to 1.06)
1.02 (0.93 to 1.13)
0.99 (0.06 to 15.59)
1.03 (0.85 to 1.26)
0.97 (0.82 to 1.14)
1.05 (0.91 to 1.20)
1.02 (0.91 to 1.14)
0.99 (0.95 to 1.03)
0.99 (0.95 to 1.03)
0.85 (0.62 to 1.15)
1.08 (0.36 to 3.27)
0.95 (0.24 to 3.77)
1.04 (0.27 to 4.01)
0.56 (0.32 to 0.99)
1.12 (0.96 to 1.31)
1.17 (0.84 to 1.64)
1.03 (0.78 to 1.36)
1.04 (0.61 to 1.75)
0.69 (0.40 to 1.18)
0.36 (0.12 to 1.12)
0.89 (0.78 to 1.01)
1.08 (0.75 to 1.55)
0.98 (0.90 to 1.06)
1.11 (0.99 to 1.25)
0.98 (0.06 to 15.43)
0.66 (0.42 to 1.04)
0.06 (0.00 to 0.98)
1.02 (0.94 to 1.11)
1.02 (0.93 to 1.12)
Excluded
Excluded
0.99 (0.94 to 1.06)
1.00 (0.96 to 1.04)
1.00 (0.97 to 1.02)
1.00 (0.97 to 1.02)
4
3
6
<1
<1
<1
<1
6
1
<1
3
8
<1
2
3
4
6
48
1
<1
<1
<1
<1
3
1
1
<1
<1
<1
5
1
12
6
<1
<1
<1
12
10
—
—
52
100
0.1 1 10
Trial
ARBs better Control better
Relative risk
(95% CI)
Relative risk
(95% CI)
Weight
(%)
265/1013
244/1514
377/1276
7/711
7/951
37/951
8/722
445/2067
87/579
11/404
295/4631
755/10 146
1/96
158/751
259/2477
364/2954
495/2511
3815/33 754
73/2354
6/120
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Fig 3 | Angiotensin receptor blockers (ARBs) and all cause mortality, stratified by comparison group (placebo v active treatment)
RESEARCH
page 6 of 14 BMJ | ONLINE FIRST | bmj.comdeath(1.00,0.97to1.02;P=0.75)(fig3),cardiovascular
death (0.99, 0.94 to 1.04; P=0.73) (fig 4), or angina
(0.95, 0.85 to 1.06; P=0.37) (fig 5) when compared
with controls. The results were similar when angioten-
sin receptor blockers were compared with either pla-
cebo or with active treatment for all of the above
outcomes (P>0.05 for interaction for all comparisons)
(figs 2-5). There was no to low heterogeneity and no
evidence for publication bias for the outcomes of
death and cardiovascular death (see figs A2-A3 in
appendix 2 on bmj.com). For the outcome of angina,
there was high heterogeneity but no evidence for pub-
lication bias (see fig A4 in appendix 2 on bmj.com).
Inaddition,angiotensinreceptorblockerswereasso-
ciated with a 10% reduction in the risk of stroke
(P=0.01) (fig 6), a 13% reduction in the risk of heart
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Fig 4 | Angiotensin receptor blockers (ARBs) and cardiovascular mortality, stratified by comparison group (placebo v active
treatment)
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BMJ | ONLINE FIRST | bmj.com page 7 of 14failure(P<0.001)(fig7),anda15%reductionintherisk
of diabetes (P<0.001) (fig 8) compared with controls.
The results were similar when angiotensin receptor
blockers were compared with either placebo or with
active treatment for all of the above outcomes
(P>0.05 for interaction for all comparisons) (fig 6-8).
There was no to moderate heterogeneity and no evi-
dence for publication bias for the outcomes of stroke
and heart failure (see figs A4-A5 in appendix 2 on
bmj.com). For the outcome of new onset diabetes,
there was moderate to high heterogeneity and no evi-
dence for publication bias (see fig A6 in appendix 2 on
bmj.com).
Trial sequential analysis
The required diversity (D
2=52%) adjusted information
size for the outcome of myocardial infarction was cal-
culated based on a proportion of 4.14% events in the
controlgroupandevaluatinginitiallyfora10%relative
risk increase (absolute risk increase of 0.4% corre-
sponding to a number needed to harm of 250) and
thenfollowedbya7.5%relativeriskincrease(absolute
risk increase of 0.3% corresponding to a number
needed to harm of 333) with angiotensin receptor
blockers, at α=5%, and β=20% (80% power) (see fig
B1 in appendix 3 on bmj.com). The cumulative z
curve crosses neither the traditional boundary nor the
trial sequential monitoring boundary but does cross
the futility boundary, suggesting firm evidence for a
lack of even an average 7.5% relative risk increase
(upper confidence limit 11%) of myocardial infarction
withangiotensinreceptorblockers(seefigB1inappen-
dix 3 on bmj.com). Similarly, the cumulative z curve
crossedthefutilityboundary,suggestingfirmevidence
forlackofonaveragea4%relativeriskincrease(upper
confidence limit 7%) in death (see fig B2 in appendix 3
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Fig 5 | Angiotensin receptor blockers (ARBs) and angina pectoris, stratified by comparison group (placebo v active treatment)
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page 8 of 14 BMJ | ONLINE FIRST | bmj.comon bmj.com), a lack of on average a 5% relative risk
increase(upperconfidence limit 5%) in cardiovascular
death(seefigB3inappendix3onbmj.com),andalack
of on average a 15% relative risk increase (upper con-
fidence limit 12%) in angina (see fig B4 in appendix 3
on bmj.com) with angiotensin receptor blockers com-
pared with controls.
Fortheoutcomeofstroke,however,thecumulativez
curve crossed the traditional boundary but not the trial
sequential monitoring boundary, suggesting lack of
evidence for a 7.5% relative risk reduction in stroke
withangiotensinreceptorblockerscomparedwithcon-
trols(seefigB4inappendix3onbmj.com).Thebound-
arywascrossed, however, forfirm evidence for at least
a 1% relative risk reduction (average 10%) in stroke
compared with placebo. When compared with active
treatment,neitherthetraditionalboundarynorthetrial
sequentialmonitoringboundarywascrossedfora15%
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Fig 6 | Angiotensin receptor blockers (ARBs) (ARBs) and stroke, stratified by comparison group (placebo v active treatment)
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BMJ | ONLINE FIRST | bmj.com page 9 of 14relativeriskreductionwithangiotensinreceptorblock-
ers. In addition, the futility boundary was not crossed,
suggesting the need for more evidence to establish
additional benefits of angiotensin receptor blockers
over active treatment. Similarly, the cumulative z
curve crossed the trial sequential monitoring bound-
ary, suggesting firm evidence for at least a 5% relative
riskreduction(average10%)inheartfailurewithangio-
tensin receptor blockers (see fig B5 in appendix 32 on
bmj.com)andatleasta4%relativeriskreduction(aver-
age 10%) in diabetes (see fig B6 in appendix 3 on
bmj.com) when compared with controls.
Sensitivity analysis
Subgroup analysis based on trial quality (low risk of
bias versus high risk of bias) and cohort enrolled
(hypertension versus non-hypertension trials) did not
make any noticeable difference for the above analyses
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Fig 7 | Angiotensin receptor blockers (ARBs) and heart failure, stratified by comparison group (placebo v active treatment)
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page 10 of 14 BMJ | ONLINE FIRST | bmj.com(table 3). The risk reduction of stroke, angina, and
heart failure was higher in trials at high risk of bias
compared with those at low risk of bias (though direc-
tionally similar) (table 3). Similarly, the risk reduction
for heart failure and new onset diabetes was higher in
hypertension trials compared with non-hypertension
trials (though directionally similar) (table 3).
DISCUSSION
In this meta-analysis we found no evidence to support
the theory that angiotensin receptor blockers increase
theriskofmyocardialinfarction.Weincluded485166
patient years of follow-up, and, with 80% power,
found, on average, a lack of 7.5% relative risk increase
(upper confidence limit 11%) (absolute increase of
0.3% corresponding to a number needed to harm of
≥333)ofmyocardialinfarctionwithangiotensinrecep-
tor blockers compared with controls. Similar results
were seen for the outcome of death, cardiovascular
death, and angina. In addition, the data provide firm
evidence for relative risk reduction of stroke (at least
1%, average 10%) (versus placebo only), heart failure
(at least 5%, average 10%), and new onset diabetes (at
least 4%, average 10%) with angiotensin receptor
blockers compared with controls.
Angiotensin receptor blockers—cardioprotection v
cerebroprotection
The 2004 results of the VALUE trial,
2 in which the
angiotensinreceptor blocker valsartan produced a sig-
nificantrelativeincreaseinmyocardialinfarctioncom-
pared with amlodipine, has fuelled a debate on the
safety of this class of drugs. In VALUE, those in the
amlodipine arm had a modest but significantly lower
blood pressure than those in the angiotensin receptor
blockers arm (1.8 mm Hg systolic and 1.5 mm Hg dia-
stolic) and a significantly lower blood pressure in the
first three months, but whether this difference can
explain the results has been contested.
1
Angiotensin II exerts most of its deleterious effects
(vasoconstriction, increased cardiac contractility, renal
tubularsodiumreabsorption,cellproliferation,vascular
and cardiac hypertrophy, inflammatory responses, and
oxidative stress) via angiotensin I receptors, while the
angiotensin II receptors counterbalance some of these
effects.Angiotensinreceptorblockersexerttheiraction
on angiotensin I receptors, which not only block the
deleterious effect of angiotensin II but also results in
overstimulation of angiotensin II receptors, probably
resulting in antihypertrophic and antifibrotic effects.
The angiotensin receptor blockers were thus thought
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Fig 8 | Angiotensin receptor blockers (ARBs) and new onset diabetes mellitus, stratified by comparison group (placebo v active
treatment)
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system but also to allow for favourable stimulation of
angiotensin IIreceptors.Morerecentstudies,however,
seem to suggest that chronic overstimulation of angio-
tensin II receptors might also exert a hypertrophic and
antiangiogenic influence on cardiovascular tissues and
that therefore the “long term consequences of ARB
therapy might be less beneficial and could even be
harmfulinsomecircumstances.”
17Inaddition,theplur-
ipotentialeffectsofangiotensinconvertingenzymeinhi-
bitorshavebeenattributedtoupstreamblockadeofthe
renin-angiotensin axis, which also inhibits the degrada-
tion of kinins to inactive metabolites resulting in raised
concentration of bioactive kinins such as bradykinin,
which has been found to have several possible benefits
suchasanti-arrhythmic effectsandreducinginfarct size
(mediated through ischaemic preconditioning and
nitric oxide/prostacyclin related vascular protection).
18
These pathophysiological mechanisms provide some
mechanistic insight intothe allegedinferiority ofangio-
tensin receptor blockers compared with angiotensin
converting enzyme inhibitors and potentially explain
the adverse outcomes.
2
Since the publication of the VALUE trial, several
large randomised trials (ONTARGET, TRANS-
CEND) have been published that showed no increase
in adverse outcomes with angiotensin receptor block-
ers. None of these trials by themselves had adequate
power for the individual outcomes. Our meta-analysis
showed firm evidence of a lack of significant effect of
angiotensin receptor blockers on myocardial infarc-
tion, ruling out even a 0.3% (number need to harm
≥333)absoluteincreaseintheriskofmyocardialinfarc-
tion with angiotensin receptor blockers. The analyses,
however, do not rule out a <0.3% absolute increase of
myocardialinfarctionwithangiotensinreceptorblock-
ers, though this is likely to be clinically less important.
The results were similar, with the cumulative z curve
crossing the futility boundary for the outcomes of
death, cardiovascular death, and angina. In addition,
there was a significant benefit for the outcomes of
stroke, heart failure, and new onset diabetes mellitus.
Whether this is due to angiotensin II receptor stimula-
tion (for example, in the brain) or to better tolerability
(and hence a better effect on blood pressure and com-
pliance) of this class of drugs is not known.
Of note, although there was no harm with treatment
with angiotensin receptor blockers, despite lower
blood pressure compared with placebo, there was no
detectable beneficial effect for the outcome of myo-
cardial infarction or cardiovascular mortality. Angio-
tensin receptor blockers, however, were as effective as
the active treatment group for these outcomes. Thus
angiotensin receptor blockers, unlike angiotensin con-
vertingenzymeinhibitorsseemnottohaveanyspecial
“cardioprotective” effects, even when compared with
placebo. In contrast, for the outcome of stroke, angio-
tensin receptor blockers were effective at reducing the
risk compared with placebo. When compared with
active treatment, there was benefit only in the fixed
effects model but not in the random effects model,
but the point estimate favoured angiotensin receptor
blockers. Trial sequential analysis, however, suggests
that we need more data before we can make robust
decisions on this outcome.
While the results from our sensitivity analysis were
largely similar, the risk reduction in trials at low risk of
bias was smaller in magnitude, although significant.
Thus the risk reduction for the outcomes of stroke,
heart failure, and new onset diabetes with angiotensin
receptor blockers is modest.
Trial sequential analysis
Conventional meta-analysis does not take into consid-
eration the information size, the number of accrued
events, and the effect size and the inference depends
onthe test forsignificanceand the confidence interval,
which can often be spuriously narrow. Not infre-
quently, non-significant results are simply inferred as
“more evidence is needed.” Trial sequential analysis
incorporates both the information size and the effect
size and is therefore helpful in making more robust
inferences. In the setting of a non-significant result,
trial sequential analysis helps decide whether “more
evidence is needed” (when the futility boundary is
not crossed) or rule out a giveneffect size (if the futility
boundary is crossed), thus reducing this uncertainty.
As can been seen in all of the analyses, while conven-
tional meta-analysis promises a greater effect size (for
significant results) or lack of small effect size (for non-
significant results), the trial sequential analysis, taking
into consideration the effect size and information size,
Table 3 |Sensitivity analysis (angiotensin receptor blockers versus controls) with numbers from random effects model
Outcomes
Relative risk (95% CI) Relative risk (95% CI)
High bias risk trials Low bias risk trials P value* Hypertension trials
Non-hypertension
trials P value*
Death 0.95 (0.82 to 1.11) 1.00 (0.97 to 1.03) 0.51 0.97 (0.92 to 1.03) 1.00 (0.97 to 1.04) 0.37
Cardiovascular death 0.94 (0.76 to 1.16) 0.99 (0.94 to 1.05) 0.64 0.98 (0.90 to 1.07) 0.99 (0.93 to 1.05) 0.85
Myocardial infarction 0.91 (0.74 to 1.11) 1.00 (0.93 to 1.09) 0.40 1.00 (0.88 to 1.14) 0.98 (0.90 to 1.08) 0.80
Stroke 0.73 (0.62 to 0.86) 0.95 (0.88 to 1.03) 0.004 0.93 (0.88 to 0.99) 0.86 (0.73 to 1.02) 0.39
Angina 0.65 (0.45 to 0.96) 1.03 (0.93 to 1.14) 0.02 0.83 (0.63 to 1.11) 0.98 (0.93 to 1.03) 0.26
Heart failure 0.70 (0.58 to 0.86) 0.90 (0.84 to 0.97) 0.02 0.77 (0.68 to 0.87) 0.93 (0.86 to 1.00) 0.01
New onset diabetes 0.60 (0.38 to 0.93) 0.87 (0.80 to 0.94) 0.11 0.76 (0.68 to 0.84) 0.93 (0.86 to 1.01) 0.003
*For interaction.
RESEARCH
page 12 of 14 BMJ | ONLINE FIRST | bmj.comismoreconservativeandprobablymoreaccurate.The
relative risk and 95% confidence interval for stroke,
heart failure, and new onset diabetes from traditional
analyses were 0.90 (0.84 to 0.98), 0.87 (0.81 to 0.93),
and 0.85 (0.78 to 0.93). For stroke there was a lack of
firmevidence(basedontrialsequentialanalysis)foran
average of 7.5% relative risk reduction with angioten-
sinreceptorblockerscomparedwiththeapparent10%
relative risk reduction suggested in the traditional
meta-analysis, the trial sequential analysis adjusted
confidence interval being 0.80 to 1.02. We therefore
needmoredatatotestfora7.5%relativeriskreduction
of stroke with angiotensin receptor blockers. For the
outcome of heart failure and diabetes, the cumulative
z curve crossed the trial sequential monitoring bound-
ary, suggesting firm evidence for a 10% relative risk
reductioninheartfailureanddiabeteswithangiotensin
receptor blockers compared with controls instead of
the 13% relative risk reduction for heart failure and
15% relative risk reduction for diabetes suggested by
the traditional meta-analysis. As trial sequential analy-
sis relies on the accumulated number of events, the
effect size, and the information size, the estimate is
more conservative and the adjusted confidence inter-
val wider but more reliable as it allows for multiple
testing on accumulating data.
Study limitations
Asinothermeta-analyses,giventhelackofdataineach
trial, we did not adjust our analyses for dose of drugs
used or compliance with assigned treatment. Though
detailed sensitivity analyses were undertaken, given
heterogeneityinthestudyprotocols,clinicallyrelevant
differences could have been missed and might be bet-
ter assessed in a meta-analysis of individual patient
data. In addition, there could be additional confoun-
ders not accounted for in the analysis. Also, not all of
the trials reported each of the outcomes analysed. The
subgroup analyses might suffer from multiple testing.
Theresultsofthesensitivityanalysesarebestdescribed
as secondary and hypothesis generating only.
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